Key Takeaways
- Record quarter, but don't annualize it: Revenue hit an all-time high, pushing EBITDA margin to an exceptional 40.5%, yet management explicitly warns this is a lumpiness artifact, not a new baseline.
- Lumpiness is the permanent reality: The same volatility that depressed Q3 delivered Q4's record; newer high-value molecules amplify swings, and management says evaluating over 10–12 quarters is the only way to see the real trend.
- Peptides framed as a second Neuland: The peptide opportunity has potential to create "another Neuland" in scale, though it will take a few years or more; a dedicated commercial facility arrives July FY27.
- Capital allocation mindset is shifting: With revenue at ₹2,000 crores and the prospect of adding ₹500–1,000 crores annually, investment decisions are moving from tactical to long-term, requiring production blocks ready for big pharma engagement.
- What to watch next quarter: Whether working capital days normalize from 137 toward historical levels, any firm peptide contracts materialize after the July facility completion, and how the new CEO/Vice Chairman structure settles in.
The Lumpiness Reality
- Q4 was exceptional, Q3 was muted: The same volatility that depressed the prior quarter delivered a record-breaking Q4; management stressed that lumpiness does not respect financial year boundaries and advised investors to assess performance over 10–12 quarters for a clear trend line.
- New molecules drive the swings: Older, stabilized molecules contribute steady revenue, but newer high-value molecules are significant in value contribution and inherently volatile; as some stabilize, new ones enter and reintroduce lumpiness.
- Margin spike is not repeatable: The 40.5% EBITDA margin reflected record revenue and uneven revenue flows; management stated it should not be seen as an indicator of future performance.
- Growth trajectory is non-linear: Management frames 18%–20% CAGR as aspirational over a 5-year period, not a year-by-year promise; FY26 ended at ₹2,000 crores versus a FY24 base of ₹1,500-plus crores.
Saharsh Davuluri: "The same lumpiness that resulted in a record-breaking Q4, if you recall, also made the previous quarter, which is Q3FY26 a relatively muted quarter. And it's worth stating the obvious. The lumpiness does not recognize financial year boundaries, right? It doesn't recognize or it doesn't care about March 31."
FY26 Performance Drivers
- CMS dominated the revenue mix: Commercial CMS projects contributed over two-thirds of revenue, with growth coming from existing pipeline products, volume ramp-ups of previously commercialized products, and one new commercialization during the year.
- Currency provided a tailwind: Rupee depreciation helped revenue, especially with many Q4 shipments benefiting from favorable exchange rates.
- Gross margin jumped on mix: Gross margin rose to 62.1% from 56.3%, driven largely by business mix; higher freight costs from the Middle East conflict were managed toward quarter-end while ensuring supply continuity.
- Full-year margin expanded sharply: EBITDA margin improved from 22.9% in FY25 to 29.4% in FY26, on revenue growth of 37.1%; management noted FY26 was a year of strong growth versus FY24, slightly better than expected aided by exchange rates.
- Working capital swelled: Working capital days rose to 137 from 107, driven by higher inventories and receivables; management expects normalization in FY27.
- Cost initiatives underway: Productivity improvements, variability reduction, operating controls, process standardization, cost governance, and procurement efficiency programs are being deployed to protect margins and build a scalable operating model.
Saharsh Davuluri: "This exceptional operating margin reflects the record high revenue this quarter. And it is also partly because of a function of the uneven nature of our revenue flows and should not be seen as an indicator of our future performance."
Peptide Strategy & Investment
- Commercial facility on track for July: The peptide facility will be ready by July as per schedule; management will focus first on completing validations, qualifications, and pre-commercialization processes before entering contracts.
- Moving beyond fragments into APIs: Large-scale peptide commercial facilities are being built to move into peptide APIs, not just fragments, expanding the scope and quality of opportunities the company can pursue.
- 8–10 programs in the pipeline: Some are advanced, some early-stage; the announced LIR Life Sciences partnership is one of these and is a very early-stage program with no near or mid-term revenue expected.
- "Another Neuland" ambition: Management believes the peptide business has potential to create "another Neuland" in terms of numbers, though it may take a few years or more depending on opportunity nature; the strategy is current capability plus peptides, not replacing small molecules, similar to how CMS scaled from 10%–15% of revenues to dominance over 5–7 years.
- Adjacencies are gradual, not urgent: On hybrid modalities like ADCs, management argued peptides are as or more attractive than oligos or ADCs, describing a gradual adjacency strategy; future adjacencies could be pursued through strategic acquisitions over time, but a decade of growth is seen in current skill sets including peptides.
Saharsh Davuluri: "I think the short answer is that it has the potential to create another Neuland for sure. It may take a few years, it may take more than a few years."
Capital Allocation & Operating Model
- Mindset shift underway: As revenue reaches ₹2,000 crores with the potential to add ₹500 crores or even ₹1,000 crores annually, capital allocation is becoming more long-term from tactical; this requires creating production blocks and being ready to engage with big pharma clients.
- ROCE expected to moderate: The company is entering longer capital deployment cycles; management is comfortable as long as investments strengthen the long-term growth engine.
- New R&D center is capability, not just capacity: The investment is described as an important step up in ability to support complex programs, building technical and problem-solving capability.
- Key account management strengthened: Dedicated resources have been put in place to support larger projects across key operating functions.
- GDS business softer in FY26: But management sees good growth potential ahead with substantial resources deployed across development, customer engagement, and capability building.
Saharsh Davuluri: "I think that's the game that needs to be played and that requires a different mindset of capital allocation, which is what was being referred to in the opening remarks."
Leadership & Organizational Updates
- Preplanned leadership transition: Effective April 1, Saharsh Davuluri became CEO and MD, Sucheth Davuluri became Vice Chairman; the transition was designed for role clarity as the business grows, with Sucheth now focusing on long-term areas including the Neuland Foundation, enterprise risk, and sustainability, while Saharsh drives day-to-day business given his 19-year tenure building the CDMO business.
- AI exploration in early days: Pilots have been done in R&D, and manufacturing data is being scanned for root cause of investigations; management is committed to bringing AI applications meaningfully into the business but describes it as very early days.
- Middle East conflict monitored closely: Raw material coverage and price volatility are being tracked; actions are being taken to protect supply continuity and manage cost pressures.
Pipeline & Demand Environment
- Visible growth for 2–3 years: Driven by existing pipeline of commercial and near-commercial molecules; one commercialization is expected in FY27, plus maybe 1 or 2 more later, but not at a quantum that changes the growth trajectory.
- Funding environment impact is contained: Business growth is driven by molecules close to commercial and clinical phases (Phase I onwards), not early discovery; the funding environment has affected early-stage pipeline but not short-to-medium-term business; molecules with good data continue to do well regardless of funding.
- Long-term groundwork being laid: Peptide and R&D investments are foundational for growth beyond the next 2–3 years.
- No formal guidance policy: Management does not intend to give formal guidance going forward.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Working capital normalization | Days to normalize from 137 toward historical levels | FY27 |
| Peptide facility completion | Facility ready; validations and qualifications to follow | July FY27 |
| One commercialization | One product entering commercial stage, possibly 1–2 more later | FY27 |
| Growth visibility | Existing pipeline of commercial and near-commercial molecules drives growth | Next 2–3 years |
| ROCE moderation | Expected as longer capital deployment cycles begin | No specific timeline |
| Volatility persistence | New molecules will continue to bring lumpiness; "25% times 4" not expected soon | Ongoing |
Key Metrics
| Metric | Q4 FY26 |
|---|---|
| Total income | ₹788.7 cr, up 134.9% YoY from ₹335.8 cr |
| CMS revenue share | Over two-thirds of total revenue in Q4 |
| Gross margin | 62.1%, up from 56.3% in Q4 FY25, driven by business mix |
| EBITDA | ₹319.4 cr, margin of 40.5%, reflecting record high revenue and lumpy flows |
| Profit after tax | ₹212.5 cr, versus ₹27.7 cr in Q4 FY25 |
| EPS | ₹165.6 per share |
| FY26 revenue | ₹2,053.1 cr, growth of 37.1% over FY25 |
| FY26 EBITDA margin | 29.4%, versus 22.9% in FY25 |
| FY26 PAT | ₹363.1 cr, EPS ₹283.01 per share |
| Free cash flow (FY26) | Negative ₹49.4 cr, driven by higher working capital and capex |
| Capex cash outflow (FY26) | ₹397.1 cr |
| Working capital days | 137 days, versus 107 days in Q4 FY25, driven by higher inventories and receivables |
| Net debt | Negative ₹157 cr, with cash balances of ₹353 cr and long-term borrowings of ₹197 cr |
| Capacity utilization | 85–90% across three units, last unit at 65% |
| Peptide CDMO market opportunity | $5–6 bn, with a healthy CAGR |